Triple inhaler shows promise for COPD sufferers
NCT ID NCT01917331
First seen Jun 25, 2026 · Last updated Jul 21, 2026 · Updated 3 times
Summary
This phase 3 trial tested a new triple-combination inhaler (beclometasone, formoterol, and glycopyrrolate) against a standard two-drug inhaler in 1,368 adults with severe COPD. The study measured changes in lung function and breathlessness over 52 weeks. The goal was to see if the triple therapy provides better symptom control and fewer flare-ups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Beclometasone, formoterol, and glycopyrrolate (triple-combination inhaler)
- What this could lead to
- If successful, this triple inhaler could offer better lung function and symptom control for people with severe COPD compared to current two-drug inhalers.
- What could go wrong
- This is a completed phase 3 trial, but results may not apply to all COPD patients. The triple inhaler may cause more side effects (e.g., throat irritation, pneumonia) and may not improve quality of life for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dr Beatrix BALINT
Szeged, 6722, Hungary
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smart breathing machines at home: a new way to predict COPD crises?
- Breathing easy? new X-Ray method may spot COPD decline early
- Could a common heart drug cut COPD hospitalizations?
- New inhaled compound aims to ease COPD breathing woes
- Ultrasound might reveal hidden lung damage in COPD
- Which inhaler breathes better? a Head-to-Head COPD showdown